15:11:01 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-14 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-07-31 Extra Bolagsstämma 2024
2024-05-30 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-03-01 X-dag ordinarie utdelning CSMED 0.00 DKK
2024-02-14 Bokslutskommuniké 2023
2023-12-15 X-dag ordinarie utdelning CSMED 0.00 DKK
2023-07-18 Kvartalsrapport 2023-Q3
2023-05-17 Kvartalsrapport 2023-Q2
2023-04-14 Extra Bolagsstämma 2023
2023-02-17 Kvartalsrapport 2023-Q1
2023-02-14 Årsstämma 2023
2023-02-10 X-dag ordinarie utdelning CSMED 0.00 DKK
2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 X-dag ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2022-06-28 08:05:00

CS MEDICA ("CS MEDICA" or the "Company") announces today that the Company has signed an distributor agreement with NaturaMedica. The agreement covers the territory of Slovenia and includes 4 of CS MEDICA's medical device products under the CANNASEN brand.  The order amounts to 20,700 units, corresponding to DKK 0,9 million in revenue which will be distributed over a 3.5-year period.

Lone Henriksen, CEO of CS MEDICA, pronounces:

"I am very glad to announce that CS MEDICA continues to expand on the European market. The Agreement with NaturaMedica demonstrates that our products are wanted and gives us a broader customer base in Europe. We hope that this agreement will spark more interest around Europe as we continue our expansion."

CS MEDICA reveals today that the Company has signed a distributor agreement with NaturaMedica. NaturaMedica (https://eur05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.naturamedica.si%2F&data=05%7C01%7C%7C06f4700858d845b39b6c08da582da188%7C1a85fb5101ea4c1581b68ca5cc0404f6%7C0%7C0%7C637919250267065005%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=OZ6MT3CsKh0oez6mTXmsL1HAeZmT0jq%2BNXGVb0vdgqQ%3D&reserved=0) is a company with a great network and extensive market know-how in Slovenia, covering both pharmacies and connections to associations as well as doctors. The focus will be on the Arthritis Gel and Pain Patch as the first launch followed by Psoriasis Gel and Nasal Spray Night later this year.

The order corresponds to DKK 0,9 million in revenue which will be distributed over a 3.5-year period. A breakdown of the annual order allocation is disclosed below.

2022:   3,200 units

2023:   3,500 units

2023:   3,600 units

2024: 10,400 units

CS MEDICA's products will be introduced to the Slovenian market later, after this summer.
 

This disclosure contains information that CS MEDICA A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 28-06-2022 08:05 CET.